Share chart Kura Oncology, Inc.
Extended chart
Simple chart
About Kura Oncology, Inc.
Kura Oncology, Inc., биофармацевтическая компания клинической стадии, разрабатывает лекарства для лечения рака в Соединенных Штатах. Его портфель состоит из кандидатов на низкомолекулярные продукты, которые нацелены на рак. more details| IPO date | 2015-09-22 |
|---|---|
| ISIN | US50127T1097 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://kuraoncology.com |
| Цена ао | 7.12 |
| Change price per day: | +2.49% (5.63) |
|---|---|
| Change price per week: | -2.04% (5.89) |
| Change price per month: | -25.16% (7.71) |
| Change price per 3 month: | -21.17% (7.32) |
| Change price per half year: | -68.05% (18.06) |
| Change price per year: | -70.38% (19.48) |
| Change price per 3 year: | -60.99% (14.79) |
| Change price per 5 year: | -29.12% (8.14) |
| Change price per year to date: | -40.76% (9.74) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Suvretta Capital Management, LLC | 7 | 9.28 |
| Blackrock Inc. | 7 | 9.06 |
| EcoR1 Capital, LLC | 6 | 7.62 |
| Deerfield Management Company, L.P. (Series C) | 5 | 7.1 |
| BVF Inc. | 5 | 6.28 |
| State Street Corporation | 4 | 5.51 |
| Vanguard Group Inc | 4 | 5.34 |
| Avoro Capital Advisors LLC | 4 | 5.05 |
| Paradigm Biocapital Advisors LP | 3 | 4.12 |
| Holocene Advisors, LP | 2 | 3.2 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Future Tech ETF | 0.15482 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.15482 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Value ETF | 0.04876 | 197.28 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.02369 | 391.25 | 1.60498 |
| 0.09 | 408.34 | 1.45 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, CEO & President | 1.06M | 1969 (56 years) |
| Ms. Kathleen Ford | Chief Operating Officer | 754.24k | 1947 (78 years) |
| Dr. Stephen Dale M.D. | Chief Medical Officer | 684.41k | 1972 (53 years) |
| Mr. Thomas Doyle | Senior Vice President of Finance & Accounting | N/A | 1971 (54 years) |
| Mr. Pete De Spain | Executive Vice President of Investor Relations & Corporate Communications | N/A | |
| Ms. Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corporate Secretary | N/A | 1971 (54 years) |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain | N/A | |
| Ms. Maureen Clancy M.B.A. | VP and Global Head of Program Leadership & Project Management | N/A | |
| Dr. Mollie Leoni M.D. | Executive Vice President of Clinical Development | N/A | |
| Mr. Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | N/A | 1974 (51 year) |
Address: United States, San Diego. CA, 12730 High Bluff Drive - open in Google maps, open in Yandex maps
Website: https://kuraoncology.com
Website: https://kuraoncology.com
